Loading
A phase 2 trial of Pafolacianine in Prostate cancer, run by Indiana University, completed.
CYTALUX™for the Intraoperative Imaging of Prostate Cancer is a phase 2 interventional study registered as NCT06434909 by Indiana University, with 9 participants recorded, started 2024-09-19 and reaching its primary completion in 2025-09-04. Interventions recorded: Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery. Conditions recorded: Prostate Cancer.
Linked to the drug Pafolacianine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pafolacianine and the tag pipeline.
Shares Pafolacianine and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/